Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Overview of attention for article published in Frontiers in Pharmacology, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,723 followers.

A good response to furmonertinib 2L Tx of an advanced lung adenocarcinoma pt w/ a rare EGFR exon 20 N771_P772insH mut: A case report and literature review ✅Furmonertinib [Ivesa®] is developed by Allist Pharma. In Mar. 2021, first approval in China. https:/

06 Sep 2022

Reply Repost Favourite

New article: Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review https://t.co/Y0hhZB7LGi #lungcancer #oncology h

05 Sep 2022

Reply Repost Favourite

New Research: Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review https://t.co/vODl5B90bN #pharmacology

17 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.